TGFB1 and myeloid sarcoma: Hashemi et al. also noticed that treatment with VitD (50 000 IU every seven days for eight weeks) in patients with MS increased the concentrations of anti-inflammatory cytokines, such as IL-27, TGF-β1 and IL-10, while the levels of pro-inflammatory interleukins, such as IL-17A and IL-6, were decreased [6].